NASDAQ:MYGNMyriad Genetics Stock Price, Forecast & News

$15.92

+0.42 (+2.71 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$15.26

Now: $15.92▼

$16.20

50-Day Range

$14.17

MA: $14.81▼

$15.92

52-Week Range

$9.24

Now: $15.92▼

$48.40

Volume1.92 million shs

Average Volume1.09 million shs

Market Capitalization$1.19 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.29

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

Beat the Market (BTM) Rank^™

3.8 Analyst's Opinion

Consensus Rating
Myriad Genetics has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on no buy ratings, 6 hold ratings, and 3 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.85, Myriad Genetics has a potential upside of 37.2% from its current price of $15.92.
Amount of Analyst Coverage
Myriad Genetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.9 Community Rank

Outperform Votes
Myriad Genetics has received 445 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Myriad Genetics has received 738 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Myriad Genetics has received 62.38% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote “Outperform” if you believe MYGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Myriad Genetics does not currently pay a dividend.
Dividend Growth
Myriad Genetics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Myriad Genetics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.90% of the stock of Myriad Genetics is held by insiders.
Percentage Held by Institutions
99.05% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Myriad Genetics are expected to grow in the coming year, from ($0.38) to $0.13 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Myriad Genetics is -7.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Myriad Genetics is -7.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Myriad Genetics has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.47 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:MYGN

Previous Symbol

CUSIP62855J10

CIK899923

Webwww.myriad.com

Phone801-584-3600

Debt

Debt-to-Equity Ratio0.29

Current Ratio3.14

Quick Ratio2.87

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$851.10 million

Price / Sales1.39

Cash Flow$2.41 per share

Price / Cash Flow6.61

Book Value$14.84 per share

Price / Book1.07

Profitability

EPS (Most Recent Fiscal Year)$1.29

Net Income$4.60 million

Net Margins-19.49%

Return on Equity1.95%

Return on Assets1.33%

Miscellaneous

Employees2,600

Outstanding Shares74,555,000

Market Cap$1.19 billion

Next Earnings Date8/11/2020 (Estimated)

OptionableOptionable

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

How has Myriad Genetics' stock been impacted by COVID-19 (Coronavirus)?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MYGN shares have increased by 13.5% and is now trading at $15.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Myriad Genetics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings and 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Myriad Genetics.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Myriad Genetics.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.10. The business earned $164 million during the quarter, compared to analysts' expectations of $167.38 million. Myriad Genetics had a positive return on equity of 1.95% and a negative net margin of 19.49%. The business's quarterly revenue was down 24.4% on a year-over-year basis. During the same quarter last year, the company posted $0.46 earnings per share. View Myriad Genetics' earnings history.

What price target have analysts set for MYGN?

9 brokerages have issued 1-year price targets for Myriad Genetics' stock. Their forecasts range from $10.00 to $36.00. On average, they expect Myriad Genetics' share price to reach $21.85 in the next twelve months. This suggests a possible upside of 37.2% from the stock's current price. View analysts' price targets for Myriad Genetics.

Has Myriad Genetics been receiving favorable news coverage?

Media headlines about MYGN stock have trended negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Myriad Genetics earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutMyriad Genetics.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 8,750,000 shares, a drop of 7.0% from the April 30th total of 9,410,000 shares. Based on an average daily trading volume, of 1,230,000 shares, the days-to-cover ratio is presently 7.1 days. Approximately 12.1% of the shares of the company are short sold. View Myriad Genetics' Current Options Chain.

Who are some of Myriad Genetics' key competitors?

Some companies that are related to Myriad Genetics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Incyte (INCY), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), STMicroelectronics (STM), Alibaba Group (BABA), Gilead Sciences (GILD) and Kratos Defense & Security Solutions (KTOS).

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:

Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.71%), Baillie Gifford & Co. (12.03%), State Street Corp (5.49%), Disciplined Growth Investors Inc. MN (4.06%), Camber Capital Management LP (3.15%) and Morgan Stanley (1.52%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View institutional ownership trends for Myriad Genetics.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., BlackRock Inc., Acadian Asset Management LLC, AQR Capital Management LLC, and Parametric Portfolio Associates LLC. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Nicole Lambert, and Richard Bryan Riggsbee. View insider buying and selling activity for Myriad Genetics.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was purchased by a variety of institutional investors in the last quarter, including Camber Capital Management LP, Federated Hermes Inc., Invesco Ltd., FDx Advisors Inc., FDx Advisors Inc., State Street Corp, Disciplined Growth Investors Inc. MN, and CWM LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, and Walter Phd Gilbert. View insider buying and selling activity for Myriad Genetics.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $15.92.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $1.19 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff